CIK 1831942
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 93.20% | 32 |
| Unclassified | 4.69% | 3 |
| Life Sciences Tools & Services | 2.11% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | RLAY | Relay Therapeutics, Inc. | Health Care | 9.79% |
| 2 | ALKS | Alkermes plc. | Health Care | 8.59% |
| 3 | ELVN | Enliven Therapeutics, Inc. | Health Care | 7.43% |
| 4 | COGT | Cogent Biosciences, Inc. | Health Care | 6.43% |
| 5 | SYRE | Spyre Therapeutics, Inc. | Health Care | 5.58% |
| 6 | TYRA | Tyra Biosciences, Inc. | Health Care | 5.48% |
| 7 | CLDX | Celldex Therapeutics, Inc. | Health Care | 4.95% |
| 8 | NUVL | Nuvalent, Inc. | Health Care | 4.94% |
| 9 | AMLX | Amylyx Pharmaceuticals, Inc. | Health Care | 4.54% |
| 10 | KYMR | Kymera Therapeutics, Inc. | Health Care | 3.61% |
33/36 names classified · sector 95.3% of weight · industry 95.3% · mkt cap 95.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 95.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 9% of book weight classified — the grid is NOT representative of the whole book.
Classified: 8.6% of book weight (1/36 names) · unclassified 91.4%: RLAY, ELVN, COGT, SYRE, TYRA, CLDX, NUVL, AMLX, KYMR, ANRO +25 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | RLAYRELAY THERAPEUTICS INC | 17,000,000 | $169M | 9.8% | HOLD |
| 2 | ALKSALKERMES PLC | 4,200,000 | $149M | 8.6% | ADD 18% |
| 3 | ELVNENLIVEN THERAPEUTICS INC | 3,275,000 | $128M | 7.4% | TRIM −30% |
| 4 | COGTCOGENT BIOSCIENCES INC | 2,888,007 | $111M | 6.4% | ADD 31% |
| 5 | SYRESPYRE THERAPEUTICS INC | 1,912,380 | $96M | 5.6% | TRIM −20% |
| 6 | TYRATYRA BIOSCIENCES INC | 2,475,000 | $95M | 5.5% | TRIM −27% |
| 7 | CLDXCELLDEX THERAPEUTICS INC NEW | 2,696,616 | $86M | 4.9% | ADD 5% |
| 8 | NUVLNUVALENT INC | 833,600 | $85M | 4.9% | ADD 52% |
| 9 | AMLXAMYLYX PHARMACEUTICALS INC | 5,650,000 | $79M | 4.5% | HOLD |
| 10 | KYMRKYMERA THERAPEUTICS INC | 750,000 | $62M | 3.6% | HOLD |
| 11 | ANROALTO NEUROSCIENCE INC | 2,723,196 | $61M | 3.5% | ADD 49% |
| 12 | PHVSPHARVARIS N V | 1,918,970 | $54M | 3.1% | HOLD |
| 13 | ERASERASCA INC | 3,175,000 | $51M | 3.0% | NEW |
| 14 | DMRADAMORA THERAPEUTICS INC | 1,939,000 | $50M | 2.9% | NEW |
| 15 | XENEXENON PHARMACEUTICALS INC | 825,000 | $48M | 2.8% | TRIM −54% |
| 16 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 2,000,000 | $38M | 2.2% | NEW |
| 17 | LBRXLB PHARMACEUTICALS INC | 1,500,000 | $37M | 2.1% | HOLD |
| 18 | EYPTEYEPOINT INC | 2,825,000 | $36M | 2.1% | NEW |
| 19 | NRIXNURIX THERAPEUTICS INC | 2,275,000 | $35M | 2.0% | HOLD |
| 20 | CRVSCORVUS PHARMACEUTICALS INC | 2,258,735 | $33M | 1.9% | NEW |
| 21 | ASMBASSEMBLY BIOSCIENCES INC | 1,000,000 | $28M | 1.6% | HOLD |
| 22 | CATXPERSPECTIVE THERAPEUTICS INC | 6,336,782 | $26M | 1.5% | NEW |
| 23 | SOLENO THERAPEUTICS INC | 652,432 | $22M | 1.3% | TRIM −46% |
| 24 | OCULOCULAR THERAPEUTIX INC | 2,575,000 | $22M | 1.3% | NEW |
| 25 | IPSCCENTURY THERAPEUTICS INC | 8,695,652 | $20M | 1.1% | NEW |
| 26 | ZURAZURA BIO LTD | 3,250,000 | $19M | 1.1% | NEW |
| 27 | SABSSAB BIOTHERAPEUTICS INC | 4,401,500 | $17M | 1.0% | HOLD |
| 28 | PALIPALISADE BIO INC | 7,181,062 | $13M | 0.7% | TRIM −37% |
| 29 | KPTIKARYOPHARM THERAPEUTICS INC | 1,950,000 | $11M | 0.6% | NEW |
| 30 | IKTINHIBIKASE THERAPEUTICS INC | 5,397,488 | $9M | 0.5% | HOLD |
| 31 | ANTXAN2 THERAPEUTICS INC | 2,333,713 | $8M | 0.5% | NEW |
| 32 | PEPGPEPGEN INC | 4,475,000 | $8M | 0.5% | ADD 32% |
| 33 | AVTXAVALO THERAPEUTICS INC | 483,000 | $7M | 0.4% | HOLD |
| 34 | HLXCHELIX ACQUISITION CORP III | 500,000 | $5M | 0.3% | NEW |
| 35 | LONALEONABIO INC | 464,398 | $5M | 0.3% | HOLD |
| 36 | RLMDRELMADA THERAPEUTICS INC | 633,901 | $4M | 0.3% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| RLAYRELAY THERAPEUTICS INC | — | — | 13.3M | 17.0M | 17.0M | 17.0M | $169M |
| ALKSALKERMES PLC | 2.3M | 1.9M | 2.5M | 3.1M | 3.5M | 4.2M | $149M |
| ELVNENLIVEN THERAPEUTICS INC | 4.2M | 4.7M | 4.7M | 4.7M | 4.7M | 3.3M | $128M |
| COGTCOGENT BIOSCIENCES INC | 6.9M | 8.9M | 2.3M | 7.3M | 2.2M | 2.9M | $111M |
| SYRESPYRE THERAPEUTICS INC | 2.0M | 2.0M | 2.0M | 2.0M | 2.4M | 1.9M | $96M |
| TYRATYRA BIOSCIENCES INC | — | 950K | 3.1M | 3.4M | 3.4M | 2.5M | $95M |
| CLDXCELLDEX THERAPEUTICS INC NEW | — | 3.2M | 3.5M | 3.0M | 2.6M | 2.7M | $86M |
| NUVLNUVALENT INC | 1.6M | 1.9M | 1.4M | 1.4M | 550K | 834K | $85M |
| AMLXAMYLYX PHARMACEUTICALS INC | — | — | — | 4.1M | 5.7M | 5.7M | $79M |
| KYMRKYMERA THERAPEUTICS INC | — | — | 750K | 750K | 750K | 750K | $62M |
| ANROALTO NEUROSCIENCE INC | — | — | — | — | 1.8M | 2.7M | $61M |
| PHVSPHARVARIS N V | 1.9M | 1.9M | 1.9M | 2.4M | 1.9M | 1.9M | $54M |
| ERASERASCA INC | — | — | — | — | — | 3.2M | $51M |
| DMRADAMORA THERAPEUTICS INC | — | — | — | — | — | 1.9M | $50M |
| XENEXENON PHARMACEUTICALS INC | 2.7M | 2.3M | 3.0M | 2.7M | 1.8M | 825K | $48M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
